BioAge Labs, Inc.
BIOANext catalyst
Oral BGE-102
Obesity and Cardiovascular Risk
Get an email about BIOA's next catalysts
Track BioAge Labs (BIOA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (data readout).See the timeline
2 upcoming, 1 past
Oral BGE-102 Phase 2 Est. Readout (QUELL-CV)
Estimated primary completion for Oral BGE-102 trial (NCT07656727) in Obesity and Cardiovascular Risk. Topline data typically follows completion by weeks to months.
SourceData Readout
BioAge has cardiovascular risk data expected in H2 2026, positioning it as a major catalyst. A rival's recent data triggered a sell-off in the sector.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oral BGE-102 | Phase 2 | Obesity and Cardiovascular Risk | - | - |
Anti-VEGF | Phase 2 | Diabetic Macular Edema (DME) | - | - |
Frequently asked questions
What is in BioAge Labs, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in BioAge Labs, Inc.'s (BIOA) pipeline across Phase 2. Its lead program is Oral BGE-102 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioAge Labs, Inc.'s next FDA catalyst?→
BioAge Labs, Inc.'s (BIOA) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BIOA biotech catalysts?→
Add BIOA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioAge Labs, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.